Enter trial of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer- Hurry

[Darryl]

malecare.org/clinical-trial

Opdivo is a medicine that may treat certain cancers by working with your immune system. Malecare, along with our partners, is prescreening our community for a study of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application. If you meet the following criteria, please go to malecare.org/clinical-trial to start your inquiry.

You must be metastatic (either regional lymph nodes or distant mets and can include bone mets)

You must be castration-resistant and receiving ongoing ADT therapy or have undergone bilateral orchiectomy

You must be chemotherapy naïve (never received chemotherapy) FOR METASTATIC DISEASE and have received 1 hormone therapy (ex. Abiraterone, enzalutamide, apalitamide, darolutamide, etc) in the metastatic setting (can have received up to 2 hormonal therapies in the non-metastatic setting)

You must live in either the USA or Canada. Sites are listed on malecare.org/clinical-trial

Start your inquiry even if you are not sure that you qualify: malecare.org/clinical-trial